Value of Voxel-Based Morphometry in Schizophrenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

96 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-20

Study Completion Date

2026-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This cross-sectional observational study investigates structural brain abnormalities in schizophrenia and nicotine use disorder (NUD), with a focus on understanding how these abnormalities correlate with behavioral traits such as decision-making and impulsivity. Schizophrenia is often associated with reduced gray matter (GM) in the prefrontal cortex and anterior cingulate cortex, while nicotine dependence is linked to changes in brain regions involved in reward processing. Nicotine use is particularly prevalent among individuals with schizophrenia, potentially compounding cognitive impairments.

Voxel-Based Morphometry (VBM), an advanced neuroimaging analysis technique, allows for the detection of subtle structural changes in the brain using MRI data. This study aims to utilize VBM to explore GM alterations in three participant groups:

Schizophrenic patients without nicotine dependence

Schizophrenic patients with nicotine dependence

Individuals with nicotine dependence but without schizophrenia

Each group will include 32 participants, making a total sample of 96, calculated using G\*Power software assuming a medium effect size, alpha 0.05, and power 0.8. Inclusion criteria include confirmed diagnoses based on DSM-5 and the Fagerström Test for Nicotine Dependence, age 18-60, and MRI compatibility. Exclusion criteria involve other psychiatric or neurological disorders, substance use other than nicotine, and MRI contraindications.

Participants will undergo:

Structural MRI scans

Behavioral assessment using the Barratt Impulsiveness Scale

Clinical interviews using the Structured Clinical Interview for DSM-5

The primary outcome is to identify distinct patterns of GM reduction or alteration across groups, especially in regions involved in decision-making (e.g., prefrontal cortex, anterior cingulate cortex) and reward processing (e.g., ventral striatum). Secondary outcomes include correlating these structural findings with impulsivity and decision-making patterns.

Statistical analysis will be performed using SPSS v26. ANOVA will be used for quantitative comparisons across the three groups, while Chi-square or Fisher's exact tests will compare categorical variables. Pearson's correlation will be used to explore associations between brain changes and behavioral traits. A p-value \<0.05 will be considered significant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia

NCT01046526

Schizophrenia Psychopathology Nicotine Dependence

COMPLETED

Brain Circuits in Schizophrenia and Smoking

NCT01369966

Schizophrenia Smoking Cessation Nicotine Abuse

COMPLETED

The Difference of Grey Matter Volume Among the Patients of Schizophrenia

NCT05262790

Schizophrenia Neuroimaging Cognitive Dysfunction

COMPLETED

Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia

NCT00407277

Smoking Nicotine Dependence Schizophrenia +3 more

COMPLETED NA

Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers

NCT00001284

Genotype Allelic Frequencies of Genetic Markers Brain Mapping +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Schizophrenia and nicotine use disorder are two conditions linked in part to distinct brain structural abnormalities that can significantly impact cognitive and behavioral functions, particularly in areas like decision-making and impulsivity. Schizophrenia (although it's exact cause is unknown) is often associated with reduced gray matter (GM) in regions such as the prefrontal cortex and anterior cingulate cortex, which are crucial for cognitive control and decision-making processes . Nicotine use disorder, on the other hand, has been linked to structural changes in brain areas involved in reward processing and impulsivity regulation. The overlap of these conditions is notable, as nicotine addiction is highly prevalent among schizophrenic patients, potentially exacerbating cognitive and behavioral dysfunctions .

Voxel-Based Morphometry (VBM) is a widely used neuroimaging technique that enables researchers to detect and quantify brain structural differences, particularly in GM, by analyzing MRI scans. VBM allows for the identification of subtle brain abnormalities that may contribute to the development of schizophrenia and nicotine dependence. These structural changes may provide insight into associated behavioral traits such as impaired decision-making and increased impulsivity, both of which are commonly observed in individuals with either or both conditions

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Schizophrenic patients without nicotine dependence

MRI

Intervention Type DIAGNOSTIC_TEST

structural MRI imaging and behavioral testing (e.g. Barratt Impulsiveness scale) both performed by skilled physicians.

Schizophrenic patients with nicotine dependence

MRI

Intervention Type DIAGNOSTIC_TEST

structural MRI imaging and behavioral testing (e.g. Barratt Impulsiveness scale) both performed by skilled physicians.

Individuals with nicotine dependence but without schizophrenia

MRI

Intervention Type DIAGNOSTIC_TEST

structural MRI imaging and behavioral testing (e.g. Barratt Impulsiveness scale) both performed by skilled physicians.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

structural MRI imaging and behavioral testing (e.g. Barratt Impulsiveness scale) both performed by skilled physicians.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed schizophrenia (for groups 1 and 2).
* Nicotine dependence as defined by the Fagerström Test for Nicotine Dependence (for groups 2 and 3).
* Age range: 18-60 years.
* Schizophrenic patients must be stable on medications for at least 2 months.
* Written informed consent (from the patient or his carer).

Exclusion Criteria

* History of other neurological or other psychiatric disorders (besides schizophrenia or nicotine dependence).
* Current substance use disorders other than nicotine.
* Severe head trauma or other conditions likely to affect brain structure.
* IQ below 70.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No